Stat proteins and oncogenesis

Journal of Clinical Investigation

Volumn 109, Issue 9, 2002, Pages 1139-1142

  Bromberg, Jacqueline ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 6; JANUS KINASE; PROTEIN TYROSINE KINASE; STAT PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE; DNA DAMAGE; HUMAN; LEUKEMIA; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0036251154     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215617     Document Type: Review

References (45)

1. STATs and gene regulation
2. The role of STATs in transcriptional control and their impact on cellular function
3. Physiological significance of STAT proteins: Investigations through gene disruption in vivo
4. Molecular aspects of primary immunodeficiencies
5. Interferons and Stats in innate immunity to microorganisms
6. What does Stat3 do?
7. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway
8. Targeted disruption of the mouse Statl gene results in compromised innate immunity to viral disease
9. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
10. Transcriptionally active Stat1 is required for the antiproliferative effects of both IFN-α and IFN-γ
11. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases
12. STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma
13. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1
14. Epidermal growth factor-induced growth inhibition requires Statl activation
15. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes
16. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation
17. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5
18. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
19. Roles of STAT3 defined by tissue-specific gene targeting
20. Stat3 as an oncogene
21. MEN2A-RET-induced cellular transformation by activation of STAT3
22. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity
23. STAT3 is constitutively activated in Hodgkin cell lines
24. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells
25. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma
26. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
27. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils
28. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation
29. STATs in oncogenesis
30. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
31. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinaseJAK2 as a result oft(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia
32. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells
33. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
34. STAT proteins: Novel molecular targets for cancer drug discovery
35. Negative regulators ofcytokine signal transduction
36. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity
37. Modulation of STAT signaling by STAT-interacting proteins
38. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma
39. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
40. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
41. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
42. Cooperation between STAT3 and c-jun suppresses Fas transcription
43. Induction of phosphorylated-Stat3 following focal cerebral ischemia in mice
44. Jak-STAT signaling pathways in cells of the immune system
45. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts